<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00638118</url>
  </required_header>
  <id_info>
    <org_study_id>M016455A_4146</org_study_id>
    <nct_id>NCT00638118</nct_id>
  </id_info>
  <brief_title>Fexofenadine HCl 180 mg, Montelukast Sodium 10 mg and Placebo in Suppression of Wheal and Flare Induced by Seasonal Allergen</brief_title>
  <official_title>A Comparison of Fexofenadine HCl 180 mg, Montelukast Sodium 10 mg and Placebo in Suppression of Wheal and Flare Induced by Seasonal Allergen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      Examine the relative potency, onset of action and duration of action of fexofenadine HCl 180&#xD;
      mg (Allegra) and montelukast sodium 10 mg (Singulair) as compared to placebo on skin wheals&#xD;
      and flares induced by seasonal allergen.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2003</start_date>
  <completion_date type="Actual">May 2003</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Size of change in skin flares from baseline will be measured.</measure>
    <time_frame>Post-dose (20 min, 40 min, 60 min, and hourly through 12 hours with an additional 2 time points obtained at Hours 23 and 24)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Size of change in skin wheals from baseline will be measured.</measure>
    <time_frame>Post-dose (20 min, 40 min, 60 min, and hourly through 12 hours with an additional 2 time points obtained at Hours 23 and 24)</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">48</enrollment>
  <condition>Allergic Rhinitis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fexofenadine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female subjects, 15 to 55 years of age, may participate.&#xD;
&#xD;
          -  Subjects with a history of seasonal allergic rhinitis (due to ragweed; oak, elm or&#xD;
             maple; or grasses) for the previous 2 years.&#xD;
&#xD;
          -  Positive seasonal allergen skin prick tests (or duplicate seasonal allergen skin prick&#xD;
             test) with a summation flare greater than or equal to 20 mm larger than diluent&#xD;
             control, and summation wheal greater than or equal to 6 mm larger than diluent control&#xD;
             at the screening visit 1 (see Appendix 17.1); the seasonal allergen testing that&#xD;
             results in the greatest summation flare will be used for all subsequent seasonal&#xD;
             allergen testing.&#xD;
&#xD;
          -  All female subjects must have a negative urine pregnancy test at the screening visit.&#xD;
&#xD;
          -  Female subjects who are sexually active will be expected to use one of the following&#xD;
             birth control methods throughout the study.&#xD;
&#xD;
          -  Subjects must be within 15% of normal body weight for height or a BMI less than 29.9&#xD;
             (based on NHLBI guidelines).&#xD;
&#xD;
          -  Subjects willing and able to adhere to visit schedules and all study requirements.&#xD;
&#xD;
          -  All female subjects must have a negative urine pregnancy test at each treatment visit&#xD;
             (Visit 2, 4, and 6).&#xD;
&#xD;
          -  Continues to meet all inclusion and exclusion criteria.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Asthma that requires treatment with medication other than an inhaled, short-acting&#xD;
             beta agonist.&#xD;
&#xD;
          -  Significant signs and symptoms of currently active allergic disease (SAR, perennial&#xD;
             allergic rhinitis, episodic allergic rhinitis).&#xD;
&#xD;
          -  Upper respiratory tract infection, sinusitis, asthma or flu-like symptoms within 2&#xD;
             weeks prior to visit 1.&#xD;
&#xD;
          -  Subjects who have dermatographism or other skin conditions which might interfere with&#xD;
             the interpretation of the skin test results.&#xD;
&#xD;
          -  Subjects who are receiving escalating doses of immunotherapy, oral immunotherapy or&#xD;
             short course (rush) immunotherapy.&#xD;
&#xD;
          -  Any excessive amounts of alcohol (no more than two drinks/day on average).&#xD;
&#xD;
          -  Any excessive use of caffeine (more than six cups of coffee per day or equivalent).&#xD;
&#xD;
          -  Any history of chronic alcohol or mood-altering drug abuse.&#xD;
&#xD;
          -  Any use of tobacco/nicotine products within 90 days of visit 1.&#xD;
&#xD;
          -  Any disease state or surgery known to affect the gastrointestinal absorption of drugs.&#xD;
&#xD;
          -  Known hypersensitivity to the investigational product or to drugs with similar&#xD;
             chemical properties.&#xD;
&#xD;
          -  Subjects who will be visiting a tanning salon during the study.&#xD;
&#xD;
          -  Subjects who will need to use artificial tanning products during the study.&#xD;
&#xD;
          -  Pregnancy.&#xD;
&#xD;
          -  Breast-feeding.&#xD;
&#xD;
          -  Regular treatment with other H1-receptor antagonists in the last year before study&#xD;
             entry.&#xD;
&#xD;
          -  No person or child of a person directly associated with the administration of the&#xD;
             study may participate as a study subject.&#xD;
&#xD;
          -  Likelihood of requiring treatment during the study period with drugs not permitted by&#xD;
             the clinical study protocol.&#xD;
&#xD;
          -  Treatment with any investigational product in the last 30 days before study entry.&#xD;
&#xD;
          -  Clinically relevant cardiovascular, hepatic, neurologic, endocrine, or other major&#xD;
             systemic disease making implementation of the protocol or interpretation of the study&#xD;
             results difficult.&#xD;
&#xD;
          -  Mental condition rendering the subject unable to understand the nature, scope, and&#xD;
             possible consequences of the study.&#xD;
&#xD;
          -  Subject unlikely to comply with protocol, e.g., uncooperative attitude, inability to&#xD;
             return for follow-up visits, and unlikelihood of completing the study.&#xD;
&#xD;
          -  Use of any of the following drugs within the time indicated prior to the first dosing&#xD;
             visit: Systemic or injected corticosteroids (including oral, parenteral, intravenous,&#xD;
             rectal) 30 days; Nasal or inhaled or ocular corticosteroids 30 days; Nasal or inhaled&#xD;
             ipratropium bromide (or atropine), inhaled nedocromil, or nasal, inhaled, or&#xD;
             ophthalmic sodium cromolyn 14 days; Agents with antihistaminic/anticholinergic&#xD;
             activity (e.g. antidepressants, antipsychotics) 14 days; Leukotriene pathway modifiers&#xD;
             (Accolate, Singulair, Zyflo) 10 days; Ocular anti-allergy medications including&#xD;
             lodoxamide (Alomide), olopatadine (Patanol), emedastine difumarate (Emadine),&#xD;
             levocabastine (Livostin) 10 days; Non-steroidal anti-inflammatory ophthalmics&#xD;
             including ketorolac (Acular), flurbiprofen (Ocufen), suprofen (Profenal), diclofenac&#xD;
             (Voltaren) 10 days; Antihistamines including desloratadine (Clarinex), loratadine&#xD;
             (Claritin) 10 days; Antihistamines including fexofenadine HCl (Allegra), cetirizine&#xD;
             (Zyrtec), hydroxyzine, azelastine nasal spray (Astelin), clemastine 7 days; Other&#xD;
             short-acting antihistamines such as chlorpheniramine or drugs with antihistaminic&#xD;
             activity 3 days; OTC oral antihistamines, decongestants (includes pseudoephedrine and&#xD;
             other decongestants), or antihistamines/decongestant combinations including all cold,&#xD;
             cough, and sleep aids 3 days; OTC ophthalmic decongestant,antihistamine, or&#xD;
             decongestant/antihistamine combinations 3 days; Other anticholinergic agents 3 days;&#xD;
             Immunotherapy injection 1 day.&#xD;
&#xD;
          -  Other drugs should only be permitted if they are not expected to interfere with the&#xD;
             ability of the subject to participate in the study.&#xD;
&#xD;
          -  Non-steroidal anti-inflammatory agents are not allowed for 2 days prior to each&#xD;
             treatment visit day through 25 hours post-dose (low-dose cardiac prophylaxis is&#xD;
             allowed).&#xD;
&#xD;
          -  Use of any medications or agents that are not specified above that may confound the&#xD;
             interpretation of the results:&#xD;
&#xD;
          -  Caffeine within 6 hours prior to each visit (coffee, tea, cola, and sodas, including&#xD;
             Mountain Dew and Surge)&#xD;
&#xD;
          -  Decaffeinated coffee, tea and colas within 6 hours of each visit&#xD;
&#xD;
          -  Alcohol within 24 hours prior to each study visit&#xD;
&#xD;
          -  Chocolate within 6 hours prior to each visit&#xD;
&#xD;
          -  Antacids within +/- minus2 hours of investigational product dosing.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Phyllis Diener</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Bridgewater</city>
        <state>New Jersey</state>
        <zip>08807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2011</verification_date>
  <study_first_submitted>March 10, 2008</study_first_submitted>
  <study_first_submitted_qc>March 17, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2008</study_first_posted>
  <last_update_submitted>January 10, 2011</last_update_submitted>
  <last_update_submitted_qc>January 10, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 11, 2011</last_update_posted>
  <responsible_party>
    <name_title>Study Director</name_title>
    <organization>sanofi-aventis</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fexofenadine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

